- Home
- SRPT vs TARS Comparison
SRPT vs TARS Comparison
Compare SRPT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | TARS |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | 370 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRPT | TARS |
|---|---|---|
| Price | $17.12 | $64.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 6 |
| Target Price | $25.85 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.7M | 649.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | 15.58 | ★ 146.71 |
| 52 Week Low | $10.42 | $38.51 |
| 52 Week High | $43.92 | $85.25 |
Technical Indicators
Market Signals| Indicator | SRPT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 50.82 |
| Support Level | $16.09 | $60.38 |
| Resistance Level | $19.32 | $67.24 |
| Average True Range (ATR) | 1.14 | 3.70 |
| MACD | -0.48 | 0.30 |
| Stochastic Oscillator | 8.24 | 74.62 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.